PROSTHETIC HEART VALVES — GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary

Key Metrics in Major Markets

<table>
<thead>
<tr>
<th>Prosthetic Heart Valves, Key Metrics in Major Markets</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2013) Global Sales Volume</td>
</tr>
<tr>
<td>(2013) Global Market Value ($m)</td>
</tr>
<tr>
<td>(2013) US Market Value ($m)</td>
</tr>
<tr>
<td>(2013) 5EU Market Value ($m)</td>
</tr>
<tr>
<td>(2013) Asia-Pacific Market Value ($m)</td>
</tr>
<tr>
<td>(2013) Brazil Market Value ($m)</td>
</tr>
</tbody>
</table>

Key Events

(2013) Edwards Lifesciences receives regulatory approval to market Sapien XT in Japan

(2014) Strong pipeline of transcatheter aortic valve replacement devices that are fully repositionable and retrievable

Forecast

<table>
<thead>
<tr>
<th></th>
<th>(2020) Global Sales Volume</th>
<th>(2020) Global Market Value ($m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2020) Global Sales Volume</td>
<td>592,257</td>
<td>$4,455.1m</td>
</tr>
<tr>
<td>(2020) Global Market Value</td>
<td>$1,527m</td>
<td></td>
</tr>
<tr>
<td>(2020) US Market Value</td>
<td>$2,319m</td>
<td></td>
</tr>
<tr>
<td>(2020) 5EU Market Value</td>
<td>$560.6m</td>
<td></td>
</tr>
<tr>
<td>(2020) Brazil Market Value</td>
<td>$48.4m</td>
<td></td>
</tr>
</tbody>
</table>

Source: GlobalData, primary research interviews with leading cardiac surgeons and interventional cardiologists in 10 markets (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil)

5EU = France, Germany, Italy, Spain, and the UK; Asia-Pacific = Japan, China, and India

The global prosthetic heart valve market in 2013 is estimated to be valued at $2,082m across the 10 major markets covered in this reported, which includes the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, India, China, and Brazil.

By the end of the forecast period in 2020, the global prosthetic heart valve market will grow to approximately $4,455m at a Compound Annual Growth Rate (CAGR) of 11.4%.

The key drivers for the market in the forecast are:

- The growing prevalence of valvular heart disease and an aging population around the globe
- Technological advancements in the field of interventional cardiology that include transcatheter aortic valve replacement (TAVR) and the desire to eliminate the need for open surgical procedures for valve replacements
- The development of TAVR devices that are fully repositionable and retrievable, providing better clinical outcomes and reducing complications associated with valve replacement procedures
Executive Summary

The US market accounts for the largest segment of the prosthetic heart valve market. While China owns a significant portion of the market in 2013, its share is expected to decrease in the forecast period due to the emergence of TAVR, which is expected to experience rapid growth and is not yet approved in China. The 5EU countries (France, Germany, Italy, Spain, and the UK) are technologically the most advanced market, with the best availability of TAVR devices. The emerging markets see the most open surgical procedures and are restricted due to the high cost of minimally invasive procedures. As training programs for surgeons and product prices reduce, the emerging markets present a strong market opportunity for additional revenue for manufacturers. The growing need for multinational companies will be to better target the fast-growing markets and continue to be a leader in development to combat the threat of rising local manufacturers.

Technological Trends

While heart valve replacement has been around for decades, minimally invasive techniques have only come into the picture recently. Modern heart valve replacements show increased durability, improved conformance to native tissue, and improved hemodynamics over older models. Advancements in diagnostic imaging have also streamlined the valve replacement process by allowing the physician to visualize the diseased valve and appropriately size the prosthetic. These imaging techniques represent an opportunity for prosthetic heart valve manufacturers to continue training programs for early detection of asymptomatic valve disease.

The technological developments in this space will continue to result in positive market growth. The primary technological drivers for TAVR devices include the development of low-profile, repositionable, and retrievable systems. Low-profile devices are of particular interest in the Asian...
Executive Summary

market, where patient arteries are smaller in diameter. Generally, there remains room for improvement in the efficacy of TAVR devices, and as the products evolve, there will be continued growth in this market.

Key Players in the Prosthetic Heart Valve Market

Currently, the prosthetic heart valve market is dominated by two players: Edwards Lifesciences and Medtronic. Medtronic has a strong presence in all three segments of this market (mechanical, tissue, and transcatheter), while Edwards has built a trusted brand in tissue valves and TAVR. In terms of transcatheter valves, these companies have launched products that are considered the gold standard in the market, and continue to innovate within this space. Direct Flow Medical and Boston Scientific are currently developing the next-generation in TAVR systems, along with the top two players, and early data from their devices have been very positive. St. Jude Medical and Sorin Group are the two big players in the surgical valve market segments (mechanical and tissue). St. Jude Medical currently manufactures what is considered the gold standard in mechanical valves, and also has a line of tissue valve products as well.

Prosthetic Heart Valve Market Future Outlook

The growth of the prosthetic heart valve market will be driven primarily by the adoption of TAVR around the globe. While surgical valves will continue to have a presence in the market, they are not expected to see rapid growth in any of the regions. Despite the high product price of TAVR, physicians recognize the clinical benefits of a minimally invasive procedure as opposed to open surgery. As physician education improves and they have access to more robust clinical data, the outlook for the TAVR market looks strong, with much room for further product improvement in next-generation devices.

The global market is expected to grow at a CAGR of 11.4%. The fastest growing markets will be Germany, Italy, and France, at CAGRs of 16.6%, 13.5%, and 12.5%, respectively. This is because a much greater number of TAVR devices are approved in the major European markets as opposed to others. The slowest growth will be seen in Brazil, India, and China, with CAGRs of 5.7%, 5.2%, and 3.3%, respectively. This is because high device cost restricts patient access to TAVR in Brazil and India, while China has not yet approved the procedure at all.

The market outlook for prosthetic heart valves looks strong in Western markets, as there is still much room for product adoption and growth. Regionally, one can expect slightly different drivers for growth. In the Western markets, availability of TAVR devices is expected to drive growth. In the Asia-Pacific (APAC) countries, lower costing devices will allow for more widespread adoption. In Japan in particular, low-profile devices will allow manufacturers to access a larger subset of patients.
Executive Summary

What Do Physicians Think?

Physicians assert that the future of TAVR is bright due to positive clinical outcomes:

“I have a conflict of interest because I do the procedure, of course, but the outlook is very positive, clearly. The results are very positive. The discussion now is: where do the indications stop?”

Key Opinion Leader

“The market opportunity is going to be to let most referring physicians and general internists and cardiologists know that there’s a whole world out there that they can offer their patients that will both improve their symptoms and lengthen their lives.”

Key Opinion Leader

High procedure and device cost is the primary barrier to adoption of TAVR in emerging markets:

“The costing is important in the US… and the costing will be important here also. There has to be a practical and pragmatic approach to that. It should not be too expensive.”

Key Opinion Leader

There is an increasing patient preference for bioprosthetic valves over mechanical valves:

“We don’t see many patients under the age of 15 needing valve surgery, but when we do, we have to emphasize to them that it probably is in their best overall long-term interest to have the mechanical valve, but sometimes that takes some persuading.”

Key Opinion Leader

Physicians mention unmet needs in the transcatheter valve space:

“…we thought the issue of severe aortic stenosis is solved if the patient has a new valve. And if he is still suffering from moderate paravalvular aortic regurgitation that will not be an issue for the patient. But actually, we were not right, and many of these patients did not really come out very well out of the procedure.”

Key Opinion Leader

“I think the only uncertainties are… the durability question, because we simply don’t have the data. I think we need to solve the Pacemaker issue, particularly in some of the device[s]… and we need to work out how we’re going to deliver… to match the demand.”

Key Opinion Leader
Executive Summary

“...we need to learn from the TAVR story and get busy in the mitral valve as well. That's the next major area for development, in my opinion... there's an opportunity waiting to be filled by somebody who can work out the easiest and safest way to put devices into the mitral position.”

Key Opinion Leader
# Table of Contents

1 **Table of Contents** .................................................................................................................. 7
   1.1 List of Tables ....................................................................................................................... 15
   1.2 List of Figures ..................................................................................................................... 21
2 **Introduction** ......................................................................................................................... 24
   2.1 Anatomy ............................................................................................................................ 24
   2.2 Epidemiology ...................................................................................................................... 24
   2.3 Related Reports ................................................................................................................... 25
3 **Industry Overview** ............................................................................................................... 26
   3.1 Overview ............................................................................................................................ 26
      3.1.1 Mechanical Heart Valves ............................................................................................ 26
      3.1.2 Tissue Heart Valves .................................................................................................... 28
      3.1.3 Transcatheter Heart Valves ......................................................................................... 29
   3.2 Indications .......................................................................................................................... 30
      3.2.1 Valvular Stenosis .......................................................................................................... 30
      3.2.2 Valvular Regurgitation ................................................................................................. 31
   3.3 Clinical Presentation ............................................................................................................ 31
      3.3.1 Diagnosis ...................................................................................................................... 31
      3.3.2 Risk Assessment Tools ............................................................................................... 31
   3.4 Clinical Outcomes .............................................................................................................. 33
      3.4.1 Treatment Options ....................................................................................................... 33
      3.4.2 Life Style Changes ........................................................................................................ 34
Table of Contents

3.4.3 Complications .................................................................................................................. 34
3.5 Applications of Technology .................................................................................................. 35
3.6 Market Access ....................................................................................................................... 35
3.6.1 Purchasing Decisions ....................................................................................................... 35
3.7 Influence of Clinical Trials ................................................................................................... 35
3.8 Brand Loyalty ....................................................................................................................... 35
3.9 Adoption ................................................................................................................................ 36
3.10 Regulation ............................................................................................................................ 37
3.10.1 US .................................................................................................................................. 37
3.10.2 5EU ................................................................................................................................. 38
3.10.3 APAC ............................................................................................................................... 39
3.10.4 South America .................................................................................................................. 42
3.11 Reimbursement ..................................................................................................................... 43
3.11.1 US .................................................................................................................................. 43
3.11.2 5EU ................................................................................................................................. 45
3.11.3 APAC ............................................................................................................................... 49
3.11.4 South America .................................................................................................................. 52
3.12 Procedure Trends .................................................................................................................. 53
3.12.1 Global Overview .............................................................................................................. 53
3.12.2 By Country ....................................................................................................................... 54
3.13 Regulatory Issues/Recalls ..................................................................................................... 75
3.13.1 Portico TAVR Implants Halted Due to Safety Concerns .................................................. 75
3.14 M&A, Key Partnerships ........................................................................................................ 75
### Table of Contents

3.14.1 Licensing Agreement Between Symetis and Endoluminal Sciences ..................................... 75
3.14.2 Manufacturing Agreement Between Sorin Group and Boston Scientific .......................... 75
3.15 Economic Impact .................................................................................................................. 75
   3.15.1 Indirect Costs ............................................................................................................. 75
   3.15.2 Direct Costs ............................................................................................................. 77

4 Unmet Needs .......................................................................................................................... 78
   4.1 Delivery & Implantation ................................................................................................. 78
   4.1.1 Mechanism of Deployment ......................................................................................... 78
   4.1.2 Anchoring .................................................................................................................. 78
   4.1.3 Retrievability .............................................................................................................. 79
   4.1.4 Repositionability ....................................................................................................... 79
   4.1.5 Artery Accessibility ..................................................................................................... 79
   4.1.6 Rapid Pacing ............................................................................................................. 80
   4.1.7 Coronary Ostia Occlusion .......................................................................................... 81
   4.1.8 Motorized Delivery Systems ....................................................................................... 81
   4.2 Performance .................................................................................................................... 82
   4.2.1 Durability .................................................................................................................. 82
   4.2.2 Thrombogenicity ....................................................................................................... 83
   4.2.3 Effective Orifice Area ............................................................................................... 83
   4.2.4 Coefficient of Friction .............................................................................................. 83
   4.3 Crimping ......................................................................................................................... 84
   4.4 Stenting ............................................................................................................................ 84
   4.5 Replaceable Leaflets ....................................................................................................... 84
## Table of Contents

4.6 Embolic Protection ........................................................................................................ 85
4.7 Pacemaker Placement .................................................................................................. 85

5 Market Opportunity Analysis ......................................................................................... 87
  5.1 Overview .................................................................................................................. 87
  5.2 Emerging Markets for TAVR .................................................................................. 87
  5.3 Increasing Tissue Valve Lifespan .............................................................................. 88
  5.4 Valve-in-Valve Procedures (Re-replacement) .......................................................... 89
  5.5 Transcatheter Mitral Valve Replacement ................................................................. 90
  5.6 Balloon Valvuloplasty .............................................................................................. 91

6 Market Drivers and Barriers ......................................................................................... 92
  6.1 Driver: Rising Disease Prevalence .......................................................................... 92
  6.2 Driver: Multimodality Imaging ................................................................................ 93
  6.3 Driver: Alternative Access Routes .......................................................................... 94
  6.4 Driver: Lower Risk Patient Access .......................................................................... 94
  6.5 Driver: Patient Demand and Awareness .................................................................. 95
  6.6 Driver: Advanced Computational Tools .................................................................... 96
  6.7 Driver: Rising Competition and Innovation ............................................................ 96
  6.8 Barrier: High Device and Procedure Cost ............................................................... 97
  6.9 Barrier: Burden of Rising Regulation ....................................................................... 97
  6.10 Barrier: Medical Device Excise Tax ....................................................................... 98
  6.11 Barrier: Proving Long-Term Efficacy .................................................................... 98
  6.12 Substitute: Valve Repair ......................................................................................... 99
  6.13 Substitute: Balloon Valvuloplasty ......................................................................... 99
# Table of Contents

7 Competitive Assessment ........................................................................................................ 100

7.1 Overview .......................................................................................................................... 100

7.2 Classification Based on Features ....................................................................................... 100

7.2.1 Mechanical Heart Valves .............................................................................................. 100

7.2.2 Tissue Heart Valves ....................................................................................................... 103

7.2.3 Transcatheter Heart Valves .......................................................................................... 106

7.3 Market Dynamics Analysis ............................................................................................... 107

7.4 Product Profiles ................................................................................................................ 109

7.4.1 Mechanical Heart Valves .............................................................................................. 109

7.4.2 Tissue Heart Valves ....................................................................................................... 115

7.4.3 Transcatheter Heart Valves .......................................................................................... 121

8 Pipeline Assessment ............................................................................................................. 135

8.1 Overview .......................................................................................................................... 135

8.2 Product Profiles ................................................................................................................ 135

8.2.1 Cytograft Tissue Valve (Cytograft Tissue Engineering) .................................................. 135

8.2.2 Centera Valve (Edwards Lifesciences) .......................................................................... 136

8.2.3 Colibri Heart Valve (Colibri Heart Valve) ................................................................... 137

8.2.4 Cormove (Perouse Medical) ......................................................................................... 138

8.2.5 Endovalve (Micro Interventional Devices) .................................................................... 139

8.2.6 HLT Transcatheter Valve System (Heart Leaflet Technology) ....................................... 140

8.2.7 Kalangos Valve (Leman Cardiovascular) ..................................................................... 141

8.2.8 Tiara Valve (Neovasc) ................................................................................................... 142

8.2.9 Trinity Valve (Transcatheter Technologies GmbH) ...................................................... 143
# Table of Contents

8.2.10 Vanguard Exchangeable Heart Valve System (ValveXchange) ................................................. 144

9 Clinical Trials to Watch ............................................................................................................. 146

9.1 Overview .................................................................................................................................. 146
9.2 CoreValve Evolut R (Medtronic) ......................................................................................... 146
9.3 TRANSFORM Trial — Intuity Valve System (Edwards Lifesciences) .................................... 146
9.4 PROACT Trial — On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies) .......... 147
9.5 PARTNER II Trial — Sapien XT (Edwards Lifesciences) ....................................................... 147
9.6 PARTNER III Trial — Sapien 3 (Edwards Lifesciences) .......................................................... 147
9.7 REPRISE III IDE/PMA Trial — Lotus Valve System (Boston Scientific) .............................. 148
9.8 SENTINEL-H Trial — Sentinel Cerebral Protection System (Claret Medical) ...................... 148

10 Current and Future Players ...................................................................................................... 149

10.1 Overview ................................................................................................................................ 149
10.2 Trends in Corporate Strategy ................................................................................................. 149
10.3 Company Profiles .................................................................................................................. 150
10.3.1 AorTech International ...................................................................................................... 150
10.3.2 Boston Scientific ............................................................................................................... 152
10.3.3 Braile Biomédica .............................................................................................................. 153
10.3.4 CardiAQ Valve Technologies ............................................................................................ 154
10.3.5 Claret Medical ................................................................................................................ 155
10.3.6 Colibri Heart Valve ......................................................................................................... 156
10.3.7 Cytograft Tissue Engineering .......................................................................................... 157
10.3.8 Direct Flow Medical ......................................................................................................... 158
10.3.9 Edwards Lifesciences ....................................................................................................... 159
## Table of Contents

10.3.10 Heart Leaflet Technologies.................................................................................... 161
10.3.11 JenaValve Technology.......................................................................................... 162
10.3.12 Leman Cardiovascular ......................................................................................... 163
10.3.13 Micro Interventional Devices ............................................................................... 164
10.3.14 Neovasc................................................................................................................ 165
10.3.15 On-X Life Technologies, Inc. .............................................................................. 166
10.3.16 Perouse Medical ................................................................................................ 167
10.3.17 Sorin Group........................................................................................................... 168
10.3.18 St. Jude Medical.................................................................................................. 169
10.3.19 Symetis ................................................................................................................ 171
10.3.20 Transcatheter Technologies GmbH .................................................................... 172
10.3.21 TTK Healthcare .................................................................................................. 173
10.3.22 ValveXchange ...................................................................................................... 174

11 Strategic Competitive Assessment ............................................................................. 176

11.1 Company Market Share .......................................................................................... 176

11.1.1 Global Overview ................................................................................................ 176
11.1.2 By Region ............................................................................................................. 177
11.1.3 By Country ........................................................................................................... 179

12 Market Outlooks by Market Segment ....................................................................... 187

12.1 Market Segment Share ............................................................................................ 187
12.1.1 Global .................................................................................................................. 187
12.1.2 By Region ............................................................................................................. 188

13 Market Outlooks by Geography .................................................................................. 192
## Table of Contents

13.1 Global Overview.............................................................................................................. 192
13.2 US.................................................................................................................................. 196
13.3 France ............................................................................................................................ 199
13.4 Germany ......................................................................................................................... 203
13.5 Italy ............................................................................................................................... 207
13.6 Spain ............................................................................................................................. 211
13.7 UK................................................................................................................................ 214
13.8 Japan ............................................................................................................................. 218
13.9 China ............................................................................................................................ 222
13.10 India ............................................................................................................................ 226
13.11 Brazil .......................................................................................................................... 230

14 Appendix.......................................................................................................................... 234

14.1 Bibliography .................................................................................................................. 234
14.2 Abbreviations ................................................................................................................ 245
14.3 Report Methodology ...................................................................................................... 248
  14.3.1 Overview ................................................................................................................ 248
  14.3.2 Coverage ................................................................................................................ 248
  14.3.3 Secondary Research ............................................................................................... 248
14.4 Forecasting Methodology .............................................................................................. 250
14.5 Physicians and Specialists Included in This Study ....................................................... 251
14.6 About the Authors ........................................................................................................ 252
  14.6.1 Analysts .................................................................................................................. 252
  14.6.2 Global Head of Healthcare .................................................................................... 253
# Table of Contents

14.7  About GlobalData........................................................................................................254
14.8  Disclaimer................................................................................................................254

## 1.1 List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1</td>
<td>Overview of Symptoms, Risk Factors, and Treatments</td>
<td>26</td>
</tr>
<tr>
<td>Table 2</td>
<td>Evolution of the Mechanical Heart Valve</td>
<td>27</td>
</tr>
<tr>
<td>Table 3</td>
<td>Evolution of the Tissue Heart Valve</td>
<td>29</td>
</tr>
<tr>
<td>Table 4</td>
<td>Comparison of Surgical and Transcatheter Procedures</td>
<td>30</td>
</tr>
<tr>
<td>Table 5</td>
<td>NYHA Functional Classification of Cardiac Disease Patients</td>
<td>32</td>
</tr>
<tr>
<td>Table 6</td>
<td>Drug Treatment Paradigm for Aortic Valve Disease</td>
<td>33</td>
</tr>
<tr>
<td>Table 7</td>
<td>Regulatory Differences Between the US and EU</td>
<td>38</td>
</tr>
<tr>
<td>Table 8</td>
<td>Medicare National Average of Inpatient Hospital Reimbursement for Valve Replacement, 2014–2015</td>
<td>44</td>
</tr>
<tr>
<td>Table 9</td>
<td>ICD-9 Coding Guide for Valvular Heart Disease, 2014</td>
<td>45</td>
</tr>
<tr>
<td>Table 10</td>
<td>Forecast Indirect National Costs For Aortic Valve Disease in the US ($bn), 2011–2020</td>
<td>76</td>
</tr>
<tr>
<td>Table 11</td>
<td>Forecast Indirect National Costs For Aortic Valve Disease in the EU ($bn), 2011–2020</td>
<td>76</td>
</tr>
<tr>
<td>Table 12</td>
<td>Minimum Arterial Diameter Required for TAVR Systems</td>
<td>80</td>
</tr>
<tr>
<td>Table 13</td>
<td>Global Projected Prevalence of Aortic Stenosis, 2013–2020</td>
<td>92</td>
</tr>
<tr>
<td>Table 14</td>
<td>Current Access Routes for Transcatheter Aortic Valve Replacement</td>
<td>94</td>
</tr>
<tr>
<td>Table 15</td>
<td>Mechanical Heart Valves, SWOT Analysis, 2014</td>
<td>101</td>
</tr>
<tr>
<td>Table 16</td>
<td>Marketed Mechanical Heart Valve Products, 2014</td>
<td>102</td>
</tr>
<tr>
<td>Table 17</td>
<td>Tissue Heart Valves, SWOT Analysis, 2014</td>
<td>104</td>
</tr>
<tr>
<td>Table 18</td>
<td>Marketed Tissue Heart Valve Products, 2014</td>
<td>105</td>
</tr>
<tr>
<td>Table 19</td>
<td>Transcatheter Heart Valves, SWOT Analysis, 2014</td>
<td>106</td>
</tr>
</tbody>
</table>
Table of Contents

Table 20: Marketed Transcatheter Heart Valve Products, 2014 ................................................................. 107
Table 21: Product Profile — Carbomedics Standard Aortic Mechanical Valve (Sorin Group) .................... 109
Table 22: Carbomedics Standard Aortic Mechanical Valve, SWOT Analysis, 2014 ................................. 110
Table 23: Product Profile — Open Pivot Mechanical Valve (Medtronic) .................................................... 111
Table 24: Open Pivot Mechanical Valve, SWOT Analysis, 2014 .............................................................. 111
Table 25: Product Profile — On-X Mechanical Heart Valve (On-X Life Technologies) ............................. 112
Table 26: On-X Mechanical Heart Valve, SWOT Analysis, 2014 .............................................................. 113
Table 27: Product Profile — On-X Plus 1.5 Mechanical Heart Valve (On-X Life Technologies) .............. 113
Table 28: On-X Plus 1.5 Mechanical Heart Valve, SWOT Analysis, 2014 ............................................... 114
Table 29: Product Profile — Regent Valve (St. Jude Medical) ................................................................. 114
Table 30: Regent Valve, SWOT Analysis, 2014 ......................................................................................... 115
Table 31: Product Profile — Carpentier-Edwards Perimount Pericardial Valve (Edwards Lifesciences) ..... 116
Table 32: Carpentier-Edwards Perimount Pericardial Valve, SWOT Analysis, 2014 ................................. 116
Table 33: Product Profile — 3f Enable Sutureless Aortic Bioprosthesis (Medtronic) ............................. 117
Table 34: 3f Enable Sutureless Aortic Bioprosthesis, SWOT Analysis, 2014 ........................................ 117
Table 35: Product Profile — Hancock II (Medtronic) ................................................................................. 118
Table 36: Medtronic Hancock II, SWOT Analysis, 2014 ........................................................................ 118
Table 37: Product Profile — Mitroflow Aortic Pericardial Heart Valve (Sorin Group) ......................... 119
Table 38: Sorin Group Mitroflow Aortic Pericardial Heart Valve, SWOT Analysis, 2014 .................... 119
Table 39: Product Profile — Trifecta Heart Valve (St. Jude Medical) ..................................................... 120
Table 40: St. Jude Medical Trifecta Heart Valve, SWOT Analysis, 2014 .................................................. 121
Table 41: Product Profile — Acurate TA/Acurate neo (Symetis) ........................................................... 121
Table 42: Acurate TA/Acurate neo, SWOT Analysis, 2014 ................................................................. 122
Table 43: Product Profile — Lotus Valve System (Boston Scientific) .................................................... 123
Table of Contents

Table 44: Boston Scientific Lotus Valve System, SWOT Analysis, 2014 .................................................. 124
Table 45: Product Profile — Direct Flow Medical Transcatheter Valve (Direct Flow Medical) ................. 125
Table 46: Direct Flow Medical Valve, SWOT Analysis, 2014 ................................................................. 125
Table 47: Product Profile — Sapien XT Valve (Edwards Lifesciences) .................................................... 126
Table 48: Sapien XT Valve, SWOT Analysis, 2014 ................................................................................. 127
Table 49: Product Profile — JenaValve (JenaValve Technology) ............................................................ 128
Table 50: JenaValve, SWOT Analysis, 2014 ........................................................................................... 128
Table 51: Product Profile — CoreValve (Medtronic) .............................................................................. 129
Table 52: CoreValve, SWOT Analysis, 2014 .......................................................................................... 130
Table 53: Product Profile — CoreValve Evolut R (Medtronic) .............................................................. 131
Table 54: CoreValve Evolut R, SWOT Analysis, 2014 .......................................................................... 131
Table 55: Product Profile — Portico Valve (St. Jude Medical) ............................................................... 132
Table 56: Portico Valve, SWOT Analysis, 2014 ...................................................................................... 132
Table 57: Product Profile — Inovare Valve (Braile Biomédica) .............................................................. 133
Table 58: Inovare Valve, SWOT Analysis, 2014 ..................................................................................... 134
Table 59: Product Profile — Cytografix Tissue Valve (Cytografix Tissue Engineering) ...................... 135
Table 60: Cytografix Tissue Valve, SWOT Analysis, 2014 ................................................................. 135
Table 61: Product Profile — Centera Valve (Edwards Lifesciences Corporation) ................................. 136
Table 62: Centera Valve, SWOT Analysis, 2014 ................................................................................... 136
Table 63: Product Profile — Colibri Heart Valve (Colibri Heart Valve) .................................................. 138
Table 64: Colibri Heart Valve, SWOT Analysis, 2014 ........................................................................... 138
Table 65: Product Profile — Cormove (Perouse Medical) ..................................................................... 139
Table 66: Cormove, SWOT Analysis, 2014 ........................................................................................... 139
Table 67: Product Profile — EndoValve (Micro Interventional Devices) ............................................... 140
Table of Contents

Table 68: Endovalve, SWOT Analysis, 2014 ................................................................. 140
Table 69: Product Profile — HLT Transcatheter Valve System (Heart Leaflet Technology) .......... 141
Table 70: HLT Transcatheter Valve System, SWOT Analysis, 2014 .................................... 141
Table 71: Product Profile — Kalangos Valve (Leman Cardiovascular) .................................. 142
Table 72: Kalangos Valve, SWOT Analysis, 2014 ............................................................ 142
Table 73: Product Profile — Tiara Valve (Neovasc.) ....................................................... 142
Table 74: Tiara Valve, SWOT Analysis, 2014 ............................................................... 143
Table 75: Product Profile — Trinity Valve (Transcatheter Technologies GmbH) ...................... 143
Table 76: Trinity VALVE, SWOT Analysis, 2014 ......................................................... 144
Table 77: Product Profile — Vanguard Exchangeable Heart Valve System (ValveXchange) ....... 145
Table 78: Vanguard Exchangeable Heart Valve System, SWOT Analysis, 2014 .................... 145
Table 79: AorTech International plc, Company Profile, 2014 ........................................... 151
Table 80: AorTech International, SWOT Analysis, 2014 .................................................. 151
Table 81: Boston Scientific Corporation, Company Profile, 2014 ........................................ 152
Table 82: Boston Scientific Corporation, SWOT Analysis, 2014 ......................................... 153
Table 83: Braile Biomédica, Company Profile, 2014 ....................................................... 154
Table 84: Braile Biomédica, SWOT Analysis, 2014 ........................................................ 154
Table 85: CardiAQ Valve Technologies, Company Profile, 2014 ....................................... 155
Table 86: CardiAQ Valve Technologies, SWOT Analysis, 2014 .......................................... 155
Table 87: Claret Medical, Inc., Company Profile, 2014 .................................................... 156
Table 88: Claret Medical, SWOT Analysis, 2014 ............................................................ 156
Table 89: Colibri Heart Valve, LLC, Company Profile, 2014 ........................................... 157
Table 90: Colibri Heart Valve, SWOT Analysis, 2014 ...................................................... 157
Table 91: Cytograft Tissue Engineering, Inc., Company Profile, 2014 ................................. 158
Table of Contents

Table 92: Cytograft Tissue Engineering, SWOT Analysis, 2014 ................................................................. 158
Table 93: Direct Flow Medical, Inc., Company Profile, 2014 .................................................................. 159
Table 94: Direct Flow Medical, SWOT Analysis, 2014 ........................................................................ 159
Table 95: Edwards Lifesciences Corporation, Company Profile, 2014 .................................................. 160
Table 96: Edwards Lifesciences, SWOT Analysis, 2014 ...................................................................... 161
Table 97: Heart Leaflet Technologies, Company Profile, 2014 ............................................................. 161
Table 98: Heart Leaflet Technologies, SWOT Analysis, 2014 ............................................................... 162
Table 99: JenaValve Technology, Company Profile, 2014 ................................................................. 162
Table 100: JenaValve Technology, SWOT Analysis, 2014 ................................................................. 163
Table 101: Leman Cardiovascular, Company Profile, 2014 ................................................................. 163
Table 102: Leman Cardiovascular, SWOT Analysis, 2014 ................................................................. 164
Table 103: Micro Interventional Devices, Inc., Company Profile, 2014 .............................................. 164
Table 104: Micro Interventional Devices, SWOT Analysis, 2014 ..................................................... 165
Table 105: Neovasc, Inc., Company Profile, 2014 .............................................................................. 165
Table 106: Neovasc, SWOT Analysis, 2014 ......................................................................................... 166
Table 107: On-X Life Technologies, Inc., Company Profile, 2014 ..................................................... 166
Table 108: On-X Life Technologies, SWOT Analysis, 2014 .............................................................. 167
Table 109: Perouse Medical, Company Profile, 2014 ........................................................................ 167
Table 110: Perouse Medical, SWOT Analysis, 2014 ......................................................................... 168
Table 111: Sorin Group, Company Profile, 2014 ............................................................................... 168
Table 112: Sorin Group, SWOT Analysis, 2014 ............................................................................... 169
Table 113: St. Jude Medical, Inc., Company Profile, 2014 ................................................................. 170
Table 114: St. Jude Medical, Inc., SWOT Analysis, 2014 ................................................................ 170
Table 115: Symetis, Company Profile, 2014 .................................................................................... 171
Table of Contents

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>116</td>
<td>Symetis, SWOT Analysis, 2014</td>
<td>171</td>
</tr>
<tr>
<td>117</td>
<td>Transcatheter Technologies GmbH, Company Profile, 2014</td>
<td>172</td>
</tr>
<tr>
<td>118</td>
<td>Transcatheter Technologies, SWOT Analysis, 2014</td>
<td>172</td>
</tr>
<tr>
<td>119</td>
<td>TTK Healthcare, Company Profile, 2014</td>
<td>173</td>
</tr>
<tr>
<td>120</td>
<td>TTK Healthcare, SWOT Analysis, 2014</td>
<td>173</td>
</tr>
<tr>
<td>121</td>
<td>ValveXchange, Inc., Company Profile, 2014</td>
<td>174</td>
</tr>
<tr>
<td>122</td>
<td>ValveXchange, SWOT Analysis, 2014</td>
<td>175</td>
</tr>
<tr>
<td>123</td>
<td>Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>188</td>
</tr>
<tr>
<td>124</td>
<td>5EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>189</td>
</tr>
<tr>
<td>125</td>
<td>APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>191</td>
</tr>
<tr>
<td>126</td>
<td>US Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>197</td>
</tr>
<tr>
<td>127</td>
<td>France Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020200</td>
<td>200</td>
</tr>
<tr>
<td>128</td>
<td>Germany Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>204</td>
</tr>
<tr>
<td>129</td>
<td>Italy Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020....</td>
<td>208</td>
</tr>
<tr>
<td>130</td>
<td>Spain Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020</td>
<td>212</td>
</tr>
<tr>
<td>131</td>
<td>UK Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020 .....</td>
<td>215</td>
</tr>
<tr>
<td>132</td>
<td>Japan Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020 .219</td>
<td>219</td>
</tr>
<tr>
<td>133</td>
<td>China Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020.223</td>
<td>223</td>
</tr>
<tr>
<td>134</td>
<td>India Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020...227</td>
<td>227</td>
</tr>
<tr>
<td>135</td>
<td>Brazil Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020 .231</td>
<td></td>
</tr>
</tbody>
</table>
Table of Contents

1.2 List of Figures

Figure 1: Hierarchy of Valvular Heart Disease ................................................................. 30
Figure 2: Operative Risk for Severe, Symptomatic Aortic Valve Disease Patients, 2009 .......... 37
Figure 3: US Procedure Volume Forecast by Market Segment, 2011–2020 ............................... 55
Figure 4: US Procedure Volume Comparison by Market Segment, 2013 & 2020 ......................... 56
Figure 5: France Procedure Volume Forecast by Market Segment, 2011–2020 ............................ 57
Figure 6: France Procedure Volume Comparison by Market Segment, 2013 & 2020 ..................... 58
Figure 7: Germany Procedure Volume Forecast by Market Segment, 2011–2020 .......................... 59
Figure 8: Germany Procedure Volume Comparison by Market Segment, 2013 & 2020 ................. 60
Figure 9: Italy Procedure Volume Forecast by Market Segment, 2011–2020 ............................... 61
Figure 10: Italy Procedure Volume Comparison by Market Segment, 2013 & 2020 ......................... 62
Figure 11: Spain Procedure Volume Forecast by Market Segment, 2011–2020 .................................. 63
Figure 12: Spain Procedure Volume Comparison by Market Segment, 2013 & 2020 ..................... 64
Figure 13: UK Procedure Volume Forecast by Market Segment, 2011–2020 .............................. 65
Figure 14: UK Procedure Volume Comparison by Market Segment, 2013 & 2020 ......................... 66
Figure 15: Japan Procedure Volume Forecast by Market Segment, 2011–2020 ............................ 67
Figure 16: Japan Procedure Volume Comparison by Market Segment, 2013 & 2020 ..................... 68
Figure 17: China Procedure Volume Forecast by Market Segment, 2011–2020 ............................ 69
Figure 18: China Procedure Volume Comparison by Market Segment, 2013 & 2020 ..................... 70
Figure 19: India Procedure Volume Forecast by Market Segment, 2011–2020 .............................. 71
Figure 20: India Procedure Volume Comparison by Market Segment, 2013 & 2020 ....................... 72
Figure 21: Brazil Procedure Volume Forecast by Market Segment, 2011–2020 ............................. 73
Figure 22: Brazil Procedure Volume Comparison by Market Segment, 2013 & 2020 ....................... 74
Figure 23: Global Company Market Shares for Prosthetic Heart Valves, 2012 .............................. 176
Table of Contents

Figure 24: EU Company Market Share for Prosthetic Heart Valves, 2012 .................................................. 178
Figure 25: APAC Company Market Shares for Prosthetic Heart Valves, 2012 ............................................. 179
Figure 26: US Company Market Shares for Prosthetic Heart Valves, 2012 ................................................ 180
Figure 27: France Company Market Shares for Prosthetic Heart Valves, 2012 .......................................... 180
Figure 28: Germany Company Market Shares for Prosthetic Heart Valves, 2012 ...................................... 181
Figure 29: Italy Company Market Shares for Prosthetic Heart Valves, 2012 ................................................. 182
Figure 30: Spain Company Market Shares for Prosthetic Heart Valves, 2012 ............................................. 182
Figure 31: UK Company Market Shares for Prosthetic Heart Valves, 2012 ............................................... 183
Figure 32: Japan Company Market Shares for Prosthetic Heart Valves, 2012 ............................................. 184
Figure 33: China Company Market Shares for Prosthetic Heart Valves, 2012 ......................................... 184
Figure 34: India Company Market Shares for Prosthetic Heart Valves, 2012 ............................................. 185
Figure 35: Brazil Company Market Shares for Prosthetic Heart Valves, 2012 .............................................. 186
Figure 36: Global Market Value Forecast by Market Segment for Prosthetic Heart Valves, $m, 2011–2020 187
Figure 37: EU Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011–2020............ 189
Figure 38: APAC Market Value Forecast by Market Segment for Prosthetic Heart Valves, 2011–2020 ......... 190
Figure 39: Global Sales Volume for Prosthetic Heart Valves, Number of Units, 2011–2020 ....................... 192
Figure 40: Global Market Value Forecast by Country, $m, 2011–2020 ......................................................... 193
Figure 41: Global Market Share Comparison by Country, 2013 & 2020 ....................................................... 195
Figure 42: US Market Value Forecast by Market Segment, $m, 2011–2020 ................................................. 196
Figure 43: US Market Value Comparison by Market Segment, 2013 & 2020 ............................................. 198
Figure 44: US Average Selling Price by Market Segment, 2011–2020......................................................... 199
Figure 45: France Market Value Forecast by Market Segment, $m, 2011–2020 ............................................ 200
Figure 46: France Market Value Comparison by Market Segment, 2013 & 2020 ....................................... 202
Figure 47: France Average Selling Price by Market Segment, 2011–2020................................................ 203
### Table of Contents

- Figure 48: Germany Market Value Forecast by Market Segment, $m, 2011–2020 .............................................. 204
- Figure 49: Germany Market Value Comparison by Market Segment, 2013 & 2020 ................................................ 206
- Figure 50: Germany Average Selling Price by Market Segment, 2011–2020 .......................................................... 207
- Figure 51: Italy Market Value Forecast by Market Segment, $m, 2011–2020 .............................................................. 208
- Figure 52: Italy Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 209
- Figure 53: Italy Average Selling Price by Market Segment, 2011–2020 ................................................................. 210
- Figure 54: Spain Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................. 211
- Figure 55: Spain Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 213
- Figure 56: Spain Average Selling Price by Market Segment, 2011–2020 ................................................................. 214
- Figure 57: UK Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................... 215
- Figure 58: UK Market Value Comparison By Market Segment, 2013 & 2020 ............................................................. 217
- Figure 59: UK Average Selling Price by Market Segment, 2011–2020 ................................................................. 218
- Figure 60: Japan Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................. 219
- Figure 61: Japan Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 221
- Figure 62: Japan Average Selling Price by Market Segment, 2011–2020 ................................................................. 222
- Figure 63: China Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................ 223
- Figure 64: China Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 225
- Figure 65: China Average Selling Price by Market Segment, 2011–2020 ................................................................. 226
- Figure 66: India Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................. 227
- Figure 67: India Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 229
- Figure 68: India Average Selling Price by Market Segment, 2011–2020 ................................................................. 230
- Figure 69: Brazil Market Value Forecast by Market Segment, $m, 2011–2020 ............................................................ 231
- Figure 70: Brazil Market Value Comparison by Market Segment, 2013 & 2020 .......................................................... 232
- Figure 71: Brazil Average Selling Price by Market Segment, 2011–2020 ................................................................. 233
Introduction

2 Introduction

2.1 Anatomy

Healthy heart valves ensure that blood flows in the proper direction at the appropriate time and with the appropriate pressure. The contraction and relaxation of the heart generates pressure differences that cause the valves to open and shut, allowing blood to fill the atria and ventricles at alternating times. The four valves in the heart are the aortic, mitral, pulmonic, and tricuspid valves. Note that the aortic, pulmonic and tricuspid valves consist of three leaflets each, while the mitral, or bicuspid, valve consists of two leaflets, anterior and posterior.

2.2 Epidemiology

Valvular heart disease (VHD) is characterized by damage to one of the four valves. The most commonly affected valves are the aortic valve, which controls blood flow between the aorta and the rest of the body, and the mitral valve, which controls blood flow between the atria and ventricles. Depending on the severity of damage, VHD can result in congestive heart failure (CHF) or other serious complications.

VHD can be treated via implantation of a prosthetic heart valve that mimics the function of a human heart valve, thus improving hemodynamics. These prostheses have a passive mode of functioning in that they open and close in response to pressure and flow changes within the heart. For the purposes of this report, the aortic and mitral valves are of primary concern because they are most commonly affected by this disorder.

Valve replacement, whether surgical or via transcatheter methods, has been shown to improve both patient morbidity and mortality outcomes. These days, surgeons utilize both open-heart as well as percutaneous valve replacement devices. However, while both the aortic and mitral valves are commonly replaced using open-heart techniques, transcatheter technology has thus far focused on the aortic valve; there are no transcatheter mitral valve replacement products on the market to date.

While the transcatheter mitral market segment is slowly growing, the majority of heart valve prosthesis global revenue is generated by three categories of devices: mechanical heart valves and tissue heart valves, which are both designed for open-heart replacement of the mitral or aortic valve, and transcatheter aortic valve replacement (TAVR). Mechanical valves are typically made...
Introduction

from non-biological materials such as metals, while tissue valves originate from animals such as pigs. The implantation of both mechanical valves and bioprosthetic valves requires surgery, while TAVR is breaking new ground as a minimally invasive technique that improves patient comfort and recovery time.

2.3 Related Reports

Appendix

14.7 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

14.8 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.